- Home
- PAM vs KYMR Comparison
PAM vs KYMR Comparison
Compare PAM & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAM
- KYMR
- Stock Information
- Founded
- PAM 1945
- KYMR 2015
- Country
- PAM Argentina
- KYMR United States
- Employees
- PAM N/A
- KYMR N/A
- Industry
- PAM Electric Utilities: Central
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- PAM Utilities
- KYMR Health Care
- Exchange
- PAM Nasdaq
- KYMR Nasdaq
- Market Cap
- PAM 3.8B
- KYMR 3.1B
- IPO Year
- PAM N/A
- KYMR 2020
- Fundamental
- Price
- PAM $68.81
- KYMR $44.64
- Analyst Decision
- PAM Buy
- KYMR Strong Buy
- Analyst Count
- PAM 3
- KYMR 16
- Target Price
- PAM $85.83
- KYMR $58.94
- AVG Volume (30 Days)
- PAM 181.9K
- KYMR 865.2K
- Earning Date
- PAM 08-06-2025
- KYMR 08-06-2025
- Dividend Yield
- PAM N/A
- KYMR N/A
- EPS Growth
- PAM 32.60
- KYMR N/A
- EPS
- PAM 0.41
- KYMR N/A
- Revenue
- PAM $1,970,436,590.00
- KYMR $58,885,000.00
- Revenue This Year
- PAM $23.47
- KYMR $58.26
- Revenue Next Year
- PAM $22.99
- KYMR N/A
- P/E Ratio
- PAM $6.92
- KYMR N/A
- Revenue Growth
- PAM 21.62
- KYMR N/A
- 52 Week Low
- PAM $38.58
- KYMR $19.45
- 52 Week High
- PAM $97.55
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- PAM 42.70
- KYMR 55.84
- Support Level
- PAM $68.09
- KYMR $43.56
- Resistance Level
- PAM $75.40
- KYMR $46.34
- Average True Range (ATR)
- PAM 2.90
- KYMR 1.81
- MACD
- PAM 0.12
- KYMR -0.60
- Stochastic Oscillator
- PAM 16.99
- KYMR 36.21
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.